Funder: University College London
Clinical trial outcomes often do not capture the breadth of the patient’s experience with respect to the physical, mental and economic impact. This refers to the experiences related to drug-resistant TB disease itself and to its treatment, especially with respect to healthcare workers individualising treatment for DRTB patients with new treatment regimens that are becoming available. Through this research project, we aim to develop outcome measures that reflect what is important to patients for use in a novel trial design to rank new DR-TB regimens. Such a trial will inform national treatment policy and clinician treatment choices and facilitate patient involvement in informed decision-making. Data collection is occurring through focus group discussions with current and previous DR-TB patients.
